The Medicare GLP-1 Bridge Program in Georgia: What It Covers and the Fine Print Nobody Explains

By Dr. Don Gates, MD, Founder of Scale Solutions

The Medicare GLP-1 Bridge is a federal demonstration program that has been live since July 1, 2026. If you qualify, you pay a flat $50 per month for certain GLP-1 medications prescribed for weight management, no matter which phase of your Part D benefit you are in. The program runs through December 31, 2027.

That is the headline, and it is genuinely useful. But the Bridge is not ordinary Part D coverage, and three details buried in the CMS program documents change the math for some beneficiaries in ways that are worth understanding before you start.

Program details verified against CMS.gov on August 19, 2026.

Key Takeaways

• Eligible Part D beneficiaries pay a flat $50 monthly copay, from July 1, 2026 through December 31, 2027.
• Only three products qualify: Foundayo, Wegovy (injection and tablets), and Zepbound — the KwikPen formulation only. Zepbound vials and single-dose pens are not covered.
• Eligibility runs through three specific BMI pathways, each with its own named conditions. “BMI over 27” alone is not enough.
• If you have type 2 diabetes, moderate-to-severe sleep apnea, or noncirrhotic MASH, you are excluded from the Bridge — because those uses are already covered under standard Part D. For most people, that is financially better news, not worse.
• The $50 copay does not count toward your Part D deductible, does not count toward the annual out-of-pocket cap, and receives no Extra Help subsidy. That combination matters, and it is explained below.

What Is the Medicare GLP-1 Bridge, Exactly?

The Bridge is a temporary CMS demonstration that sits outside the normal Part D benefit. CMS states plainly that eligible drugs furnished under the program “are provided outside of the Part D benefit payment flow and coverage.”

That phrasing is not bureaucratic decoration. It is the reason for almost everything else in this article. Because the Bridge is not a Part D benefit, the ordinary Part D protections — the deductible, the annual out-of-pocket cap, the low-income subsidy — do not attach to it.

Mechanically, participating manufacturers supply the drugs at a net price of $245 per monthly supply, a central processor (Humana) handles prior authorization and pharmacy payment, and your pharmacy collects $50 from you. You must be enrolled in an eligible Part D plan — a standalone drug plan or a Medicare Advantage plan with drug coverage — for any of this to work.

Which Medications Are Covered?

Three products, and the formulation details matter:

The Zepbound restriction is the trap. Many patients currently use Zepbound single-dose vials or the single-dose pen. Neither is covered under the Bridge. If you are on vials and expect a $50 copay, your pharmacy claim will not process as you assume.

This is fixable, but it requires a conversation with your prescriber about whether switching to the KwikPen is appropriate for you. The KwikPen is a multi-dose pen with different handling and dosing than a single-dose vial and syringe — not a swap to sort out at the pharmacy counter.

Who Qualifies? The Three BMI Pathways

You must be enrolled in an eligible Part D plan, be at least 18 years old, and meet the clinical criteria at the time you start GLP-1 therapy. The prescription must be written, in CMS’s words, “to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification.”

Then you need one of these three pathways:

1. BMI of 35 or higher — no additional condition required.

2. BMI of 30 or higher, plus at least one of: – Heart failure with preserved ejection fraction – Uncontrolled hypertension, which CMS defines specifically as systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite concurrent treatment with two antihypertensive medications – Chronic kidney disease, stage 3a or above

3. BMI of 27 or higher, plus at least one of: – Pre-diabetes – Previous myocardial infarction (heart attack) – Previous stroke – Symptomatic peripheral artery disease

Note how specific these are. The BMI 30 pathway does not accept “high blood pressure” generally — it requires blood pressure still above target while already on two medications. The BMI 27 pathway does not accept high cholesterol, arthritis, or fatty liver. These criteria are narrower than the FDA-approved prescribing criteria for the drugs themselves, and narrower than most articles suggest.

Timing matters too: you must meet the criteria at initiation of therapy. Losing weight successfully and dropping below a threshold later does not disqualify you.

Why Diabetes, Sleep Apnea, and MASH Are Excluded

If you have been diagnosed with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced fibrosis, you are not eligible for the Bridge.

This surprises people, and it sounds like a denial. It generally is not. CMS’s rule is that “a beneficiary diagnosed with a condition that is currently eligible for coverage under Part D is not eligible for the Medicare GLP-1 Bridge.” Those three conditions already have FDA-approved GLP-1 indications that standard Part D can cover. The Bridge exists to reach people who have no Part D route at all.

Here is the part worth sitting with: for most people, standard Part D coverage is the better financial position. Under standard Part D, what you pay counts toward your deductible, counts toward your annual out-of-pocket cap, and — if you receive Extra Help — is subsidized down to a nominal amount. None of that is true under the Bridge. Being routed to Part D instead of the Bridge is frequently good news.

Related: Zepbound’s FDA-approved sleep apnea indication.

⭐ The Fine Print: Three Things That Change the Math

These three facts appear in CMS’s own program documents and almost nowhere in patient-facing material.

1. The copay does not count toward your Part D deductible. CMS: the Part D deductible does not apply, and “no part of the $245 net price for eligible GLP-1 drugs prescribed for uses covered under the Medicare GLP-1 Bridge would count toward an eligible beneficiary’s gross covered prescription drug costs (GCPDC).”

2. The copay does not count toward your annual out-of-pocket cap. CMS: “no part of the $50 copay would count toward the beneficiary’s true out-of-pocket costs (TrOOP) under their Part D plan.” The Part D cap is $2,100 in 2026. Your Bridge spending sits entirely outside it.

3. Extra Help does not apply. CMS: “low-income cost-sharing subsidies would also not apply to any portion of the copay.”

What this means in practice

$50 a month is $600 a year, and that $600 is additive and uncapped. It does not draw down your deductible, and once your other prescriptions push you past the $2,100 out-of-pocket cap, the cap does not protect this $50. You keep paying it every month regardless.

Two groups should look closely at their own numbers:

• Beneficiaries receiving Extra Help. If you have the low-income subsidy, you are used to paying a few dollars for a covered prescription. The Bridge copay is not subsidized at all. Going from nominal copays to an unsubsidized $50 every month is a substantial change to a fixed budget.
• Beneficiaries with high total drug spending. If your other medications already carry you to the $2,100 cap, everything else becomes free for the rest of the year — except this. The Bridge copay continues on top.

The honest conclusion: depending on your total drug spending and your subsidy status, it is possible to pay more overall under the Bridge than a comparable person would pay for a drug covered through standard Part D. This is not true for everyone — for many people the Bridge is still by far the cheapest route, since the self-pay price of these medications runs several hundred dollars a month. But it is genuinely circumstance-dependent, turning on arithmetic specific to your plan, your subsidy status, and your full medication list.

That decision belongs to you, with real numbers in front of you. It is worth ten minutes with your pharmacist, your plan’s benefits counselor, or your local State Health Insurance Assistance Program before assuming the Bridge is automatically your cheapest option.

How It Works Mechanically

• Your prescriber does not need to be enrolled in Medicare to write the prescription or submit the prior authorization.
• Your prescriber must not be on the CMS Preclusion List.
• The prior authorization comes after the pharmacy claim, not before. CMS instructs prescribers to send the prescription to the pharmacy and wait for the pharmacy to request the authorization. Submitting it early produces a “patient not found” error — a common source of avoidable delay.
• Your prescriber attests to your eligibility under penalty of perjury. This is why a physician who has reviewed your chart, your blood pressure readings, your kidney function, and your medication list is the right person to handle it. The attestation is a legal statement about your clinical criteria.
• Manufacturer coupons and discount cards cannot be applied to Bridge claims.

What Happens After December 31, 2027?

Honestly: nobody knows yet, and anyone telling you otherwise is guessing.

The Bridge is authorized through December 31, 2027. The program that was widely expected to succeed it — the Part D portion of the CMS BALANCE Model — is not arriving on schedule. On April 21, 2026, CMS announced it “will delay implementation of the Medicare Part D portion of Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) Model for Calendar Year (CY) 2027 pending further evaluation and data collection.” That delay is open-ended.

CMS has not said what follows the Bridge. That uncertainty is a legitimate thing to factor into planning, because stopping a GLP-1 abruptly is not a neutral event — trial evidence consistently shows substantial weight regain and reversal of cardiometabolic improvements after discontinuation. If you start on the Bridge, it is reasonable to ask your physician early what your options would look like if the program is not renewed.

Related: what the evidence shows about stopping a GLP-1.

Why This Matters More in Georgia

Georgia Medicaid does not cover weight-loss medications. Georgia’s State Plan Amendment GA-24-0001 explicitly excludes “agents used for anorexia, weight loss or weight gain,” and the current Georgia Preferred Drug List reflects that — Wegovy, Zepbound, Saxenda, Contrave, and Qsymia do not appear. Georgia is not among the states covering GLP-1s for obesity under Medicaid. For dually eligible Georgians and for many others, the Bridge is not one option among several. It is the option.

TRICARE For Life beneficiaries near Fort Stewart: read this carefully

On August 31, 2025, the Defense Health Agency ended weight-loss drug coverage for TRICARE For Life beneficiaries, direct-care-only beneficiaries, and NATO/Partnership for Peace beneficiaries. Previously approved prior authorizations became invalid that day. With more than 19,000 military retirees living in the communities around Fort Stewart and Hunter Army Airfield, this affected a lot of people here.

TRICARE’s own weight-loss products page now points those beneficiaries toward this program, stating that “beginning July 1, 2026, Medicare Part D covers certain weight loss drugs under the Medicare GLP-1 Bridge Program.”

But there is a step in between that is easy to miss. The Bridge requires enrollment in an eligible Part D plan. Most TRICARE For Life beneficiaries receive their prescription coverage through the TRICARE Pharmacy Program and are not enrolled in Part D — which means they are not currently eligible for the Bridge, even though TRICARE is pointing them to it. TRICARE’s page acknowledges this indirectly by linking beneficiaries to information about when they can enroll in Part D.

Enrolling in Part D is a real decision with premium costs, enrollment-period timing, and possible late-enrollment penalties attached. It is not something to do casually on the strength of a $50 headline. If you are a TRICARE For Life beneficiary weighing this, a benefits counselor should walk you through the full cost picture before you enroll.

When to Talk to Your Doctor

Schedule a routine visit if you want to know whether you meet the Bridge criteria, if you are currently using Zepbound vials and need to understand the KwikPen restriction, if your prior authorization was denied and you do not know why, or if you want your eligibility documented properly before the program’s clock runs down.

Seek prompt medical attention — not a routine appointment — for severe or persistent abdominal pain (particularly pain radiating to the back, which can signal pancreatitis), persistent vomiting with signs of dehydration, signs of an allergic reaction, or any new vision changes. These are not billing questions. They are clinical ones, and they should not wait on a coverage conversation.

Scale Solutions & Coastal Georgia

Coverage questions and clinical questions are tangled together in this program in a way they usually are not. Your prescriber has to attest, under penalty of perjury, that you meet criteria defined by your blood pressure on two medications, your kidney function staging, or your documented cardiovascular history. That is not paperwork a provider can do well without knowing you.

That is the practical case for a physician nearby who has your chart, labs, blood pressure trend, and medication list in front of them — someone who can document eligibility accurately the first time, catch a formulation problem before it becomes a rejected claim, monitor you properly once you start, and think through what happens when the program window closes at the end of 2027.

If you live in Savannah, Pooler, Richmond Hill, Hinesville, or anywhere in Coastal Georgia and you have questions about whether the Bridge applies to you, you are welcome to reach out to Scale Solutions. We are glad to help you sort out where you stand, including telling you plainly if the Bridge is not your best route.

Related: check where your BMI falls.

Related: what these medications cost in Georgia without coverage.

Related: GLP-1 safety considerations for adults over 60.

Related: TRICARE weight-loss coverage near Hinesville and Fort Stewart.

Related: how we monitor patients on GLP-1 therapy.

Frequently Asked Questions

How much does the Medicare GLP-1 Bridge cost? A flat $50 per month per eligible prescription, regardless of which Part D benefit phase you are in. There is no deductible to meet first. The program runs from July 1, 2026 through December 31, 2027.

Does the $50 copay count toward my Part D out-of-pocket cap? No. CMS states that no part of the $50 copay counts toward your true out-of-pocket costs. Bridge spending sits entirely outside the $2,100 annual cap for 2026, so reaching that cap on your other drugs does not eliminate the $50.

I have Extra Help. Does it cover the Bridge copay? No. CMS states that low-income cost-sharing subsidies do not apply to any portion of the copay. If you receive Extra Help, this is worth reviewing with a benefits counselor, because $50 unsubsidized each month is a meaningful change from the nominal copays you likely pay for your other prescriptions.

I use Zepbound vials. Am I covered? Not under the Bridge. Only the Zepbound KwikPen formulation is included. Wegovy and Foundayo are covered in all formulations. If you are on vials, talk with your prescriber about whether the KwikPen is appropriate for you.

I have type 2 diabetes. Why was I turned down for the Bridge? Because type 2 diabetes already has a Part D coverage route. The Bridge is designed for people who have no Part D pathway. Standard Part D coverage generally treats you better financially — it counts toward your deductible and your out-of-pocket cap, and Extra Help applies to it.

Can TRICARE For Life beneficiaries use the Bridge? Only if they are enrolled in an eligible Medicare Part D plan. Most TRICARE For Life beneficiaries get prescription coverage through the TRICARE Pharmacy Program rather than Part D, which makes them ineligible unless they enroll. Enrolling in Part D carries premiums and enrollment-timing consequences worth reviewing with a benefits counselor first.

Does Georgia Medicaid cover Wegovy or Zepbound for weight loss? No. Georgia’s Medicaid state plan excludes agents used for weight loss, and these medications do not appear on the Georgia Preferred Drug List for that use.

What happens when the program ends in 2027? CMS has not announced a successor. The Part D portion of the BALANCE Model, expected to follow, was delayed by CMS on April 21, 2026 pending further evaluation, with no new date. Plan for the uncertainty rather than assuming continuity.

Conclusion

The Medicare GLP-1 Bridge is a real and meaningful opening — for many Coastal Georgia patients it is the difference between a covered medication and no medication at all. It is also narrower and more conditional than the “$50 a month” headline suggests: three specific eligibility pathways, a formulation restriction that will catch Zepbound vial users off guard, a copay that touches neither your deductible nor your out-of-pocket cap, no Extra Help subsidy, and an expiration date at the end of 2027 with nothing announced to follow it. None of that makes it a bad program. It makes it one worth entering with clear eyes and accurate numbers.

If you are in Savannah or Coastal Georgia and want a straight answer about whether you qualify, whether your current medication and formulation fit the program, or what your options are if the Bridge is not right for you, contact Scale Solutions. We will look at your actual situation and give you an honest read — that is what a local medical practice is for.

MEDICAL SOURCES & FURTHER READING

1. CMS — Medicare GLP-1 Bridge (program overview). Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge (accessed August 19, 2026)
2. CMS — Medicare GLP-1 Bridge: Information for Providers. Eligibility criteria, BMI pathways, prescriber requirements, Preclusion List, prior authorization sequence, penalty-of-perjury attestation. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers (accessed August 19, 2026)
3. CMS — Medicare GLP-1 Bridge: Information for Pharmacies. Eligible drugs and formulations including the Zepbound KwikPen restriction; central processor; dispensing fees; outside-Part-D structure. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies (accessed August 19, 2026)
4. CMS — Medicare GLP-1 Bridge: Information for Part D Plans. Source of the verbatim GCPDC, TrOOP, and low-income cost-sharing subsidy language. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans (accessed August 19, 2026)
5. CMS — Medicare GLP-1 Bridge Expectations and FAQs (PDF). $245 net price; excluded conditions; “condition currently eligible for coverage under Part D” rule. https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf (accessed August 19, 2026)
6. CMS — Status Update: BRIDGE Demonstration and BALANCE Model in Part D for CY 2027. HPMS memorandum dated April 21, 2026. https://www.cms.gov/files/document/status-update-bridge-demo-balance-model-part-d-cy2027-g-pdf.pdf
7. Medicare.gov — How much does Medicare drug coverage cost? 2026 maximum deductible ($615) and annual out-of-pocket cap ($2,100). https://www.medicare.gov/health-drug-plans/part-d/basics/costs (accessed August 19, 2026)
8. TRICARE — Weight Loss Products. August 31, 2025 coverage change; excluded beneficiary categories including TRICARE For Life; referral to the Medicare GLP-1 Bridge as of July 1, 2026. https://tricare.mil/weightlossproducts (accessed August 19, 2026)
9. Medicaid.gov — Georgia State Plan Amendment GA-24-0001. Excluded outpatient drug categories, including “agents used for anorexia, weight loss or weight gain.” https://www.medicaid.gov/medicaid/spa/downloads/GA-24-0001.pdf
10. Georgia Medicaid Preferred Drug List, effective August 1, 2026. https://fm.formularynavigator.com/FBO/4/Georgia_PDL_English.pdf
11. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14725
12. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. DOI: 10.1001/jama.2023.24945

Editorial standards for Scale Solutions content: https://scale-solutions.com/editorial-policy/